• MongoDB (MDB) was the clearest short-term long: the host favored buying around $325 and expected $340 by the end of the day; treat that as a high-risk, same-day trade, not a long-term target.
• Micron (MU) earnings were flagged for the following day as a potential volatility catalyst; monitor results and guidance before taking a position.
• The host remains bearish on Kodiak Sciences (KOD) and estimates it may be $50–$60 or more overvalued, but crowded short interest and squeeze risk make shorting especially risky.

uniQure (QURE)

• The host said they traded uniQure for a profit, though the entry price was unclear in the transcript; they said they sold at $20.
• They argued that the news discussed should not change the regulatory review, while acknowledging investors may be nervous during a sensitive review period. The stock had previously been around $40 while awaiting that review.
• They considered buying again on a pullback but said they were unsure whether to re-enter.

Takeaways

• The discussion frames QURE as a regulatory catalyst trade, with sentiment dependent on how investors interpret the news and the pending review. The host did not give a firm buy recommendation; a pullback was mentioned only as a possible entry point.

Kodiak Sciences (KOD)

• The host remained bearish on Kodiak’s data and said they had re-established a short position after covering earlier. They described the data as poor and argued that the drug candidates may not offer enough benefit over existing treatment.
• They cited concerns about the trial design and interpretation of results, including the lack of a controlled, blinded comparison and questions about whether the drug could meaningfully compete with Eylea.
• The host estimated the stock might be $50–$60 or more overvalued, but stressed that price action and short squeezes had made the trade difficult. They acknowledged that even a drug they consider weak could generate meaningful revenue in a large ophthalmology market.
• Short interest and a crowded trade were identified as important risks to the bearish position.

Takeaways

• The host’s fundamental view was bearish, but the transcript also illustrates the danger of shorting a stock with high short interest and strong upward momentum. The stated valuation view is the host’s estimate, not a confirmed price target.

Summit Therapeutics (SMMT)

• Summit rose after AstraZeneca announced a $2 billion investment and partnership. The host was unsure how meaningful the deal was, noting it was an investment rather than a licensing agreement and speculating that the stock might give back some gains.
• They also said partnerships can be valuable when they lead to combination clinical trials, because that may help establish use of a drug alongside a larger company’s treatments.

Takeaways

• The partnership was viewed as potentially helpful for collaboration and product adoption, but the host did not treat the investment alone as proof of commercial success. The transcript offered no price target or firm recommendation.

Iovance Biotherapeutics (IOVA)

• The host noted that Iovance had rallied sharply and described it as potentially overextended, with the possibility of a pullback.
• They also observed that the company appeared to have few fundamental institutional shareholders and suggested that low ownership could create demand if more investors decided they needed exposure.
• The discussion mentioned a recent guidance increase and a move from roughly $8 to $13. The host questioned whether shorting the stock made sense given its momentum and potential institutional interest.

Takeaways

• The discussion presents competing forces: a sharp rally that could reverse, and relatively low ownership that could support further buying. The host did not settle on a clear long or short view.

Moderna (MRNA)

• Moderna was described as a stock to watch amid a broad squeeze in healthcare names. The host said they made quick profits trading it and considered shorting again if it rallied.
• The stock later weakened, but the host also observed that other squeezed stocks had repeatedly cooled off before rallying again.

Takeaways

• The host treated MRNA as a volatile trading opportunity rather than making a long-term fundamental case. The transcript highlights the risk of relying on a pullback in a stock experiencing strong momentum.

MongoDB (MDB)

• The host expressed a favorable short-term view and urged a colleague to buy more around $325, saying they expected the stock could reach $340 by the end of the day. This was a specific trading opinion in the discussion, not a longer-term target.
• In its presentation, MongoDB emphasized growth in larger customers, subscription ARR, and Atlas. Management said larger customers were continuing to drive revenue growth and that Atlas growth was consistent with revenue growth.
• The host said the company might provide guidance or other information on its call.

Takeaways

• The bullish discussion centered on customer expansion and recurring-revenue growth. The $340 figure was a same-day trading expectation, not a stated long-term valuation.

Carnival (CCL)

• The host said an automated trading bot bought Carnival before the stock rose 11%. They later said they sold the position.

Takeaways

• CCL was discussed as a successful short-term trade, not as a fundamental investment thesis. No longer-term outlook or recommendation was provided.

Applied Optoelectronics (AAOI)

• The host called AAOI one of the market’s wildest stocks and described it as a momentum name and a useful gauge of speculative retail activity.
• They said the company makes a commodity-like product, called the chart weak, and suggested it could be a short. They also noted that demand for its products was strong and advised starting small if trading it.

Takeaways

• The discussion is mixed: speculative momentum and strong demand could support the stock, while the host’s concerns about the business and chart point the other way. The host specifically cautioned against starting with a large position.

Invivyd (IVVD)

• The host estimated the company’s enterprise value at about $128 million and said it had a real product with some revenue, while noting that COVID had not disappeared.
• They saw a highly uncertain outlook: if COVID resurged, the stock could rise substantially; if not, the company might be left with limited revenue and an unclear growth plan. The host said they did not fully understand the fundamental case and wanted to speak with the CEO.

Takeaways

• The discussion presents IVVD as a highly uncertain, COVID-dependent opportunity. The host’s comments point to both possible upside from renewed demand and the risk of weak growth if demand remains limited.

Bloom Energy (BE)

• The host said Bloom Energy looked strong and connected its opportunity to continued data-center construction. They described its fuel-cell technology as a potential solution for power needs.
• Nuclear power was also discussed as a possible source of energy, but the host called it less practical to build and regulate in the near term, while noting that small modular reactors were still not widely deployed.

Takeaways

• The investment theme is rising demand for power to support data centers, with fuel cells presented as one possible solution. The transcript did not provide a valuation, price target, or specific recommendation.

BeyondSpring (BYSI)

• The host questioned why the market reacted negatively to news involving a Fast Track designation and a strategic transaction, saying the stock was down despite what sounded like positive news.

Takeaways

• The discussion noted a divergence between the apparent news tone and the share-price reaction, but offered no fundamental assessment or recommendation.

Semiconductor and AI-related stocks

• The host described Micron (MU) as a key upcoming event, saying its earnings the following day could make for a major trading session.
• NVIDIA (NVDA), AMD (AMD), Taiwan Semiconductor (TSM), SanDisk (SNDK), Intel (INTC), ASML (ASML), Lam Research (LRCX), Applied Materials (AMAT), Broadcom (AVGO), Arm (ARM), Texas Instruments (TXN), Qualcomm (QCOM), and Marvell (MRVL) were discussed as trading names or additions to a colleague’s watchlist.
• The host mentioned trading results in some of these names but did not give a broad directional view on the group. SK Hynix was also mentioned in connection with trading activity.
• The host discussed continued data-center construction as a driver of power demand, linking that theme to AI infrastructure.

Takeaways

• The actionable focus in the transcript was on monitoring individual names and upcoming company news, especially Micron’s earnings—not on a blanket recommendation to buy semiconductor stocks. Event-driven moves and volatility were central to the discussion.

OpenAI (private company)

• OpenAI was mentioned in connection with a reported $1.4 trillion fundraise and an ARR figure of $70 billion.
• The host argued that a major IPO does not automatically force investors to sell other stocks, since existing shares can simply become publicly tradable. They also noted that IPOs can affect liquidity and that some early investors may choose to sell.

Takeaways

• The discussion focused on IPO mechanics and market liquidity, not on a direct investment recommendation. OpenAI was discussed as a private-company opportunity; no public ticker, valuation, or investor access method was provided.

Other healthcare and biotechnology mentions

• Ultragenyx (RARE) was cited as an example of a company the host viewed favorably as a value investor.
• Zentalis Pharmaceuticals (ZNTL) was described as developing a WEE1 inhibitor for platinum-resistant ovarian cancer. The host said they were not sure what the company was doing with the program and did not offer a view on its prospects.
• Nektar Therapeutics (NKTR) was mentioned, but the host said they did not know enough about it to trade it.
• Ginkgo Bioworks (DNA) was mentioned without a substantive investment view.
• The host also named Pfizer (PFE), Merck (MRK), Eli Lilly (LLY), Johnson & Johnson (JNJ), Novartis (NVS), and GSK (GSK) while expressing general support for pharmaceutical companies and vaccines. No company-specific investment analysis was given.

Takeaways

• These mentions did not amount to clear recommendations. The only explicit positive investment view in this group was the host’s general description of Ultragenyx as a value-oriented holding; the other names were mentioned briefly or without enough analysis to draw a thesis.

Energy Vault (NRGV)

• Energy Vault appeared briefly while the host was scanning stocks. No company-specific analysis, sentiment, or trading plan was provided.

Takeaways

• The transcript did not provide enough information to form an investment view on NRGV.